| Autor: |
Alec W. Freyn, Caroline Atyeo, Patricia L. Earl, Jeffrey L. Americo, Gwo-Yu Chuang, Harini Natarajan, Tiffany Frey, Jason Gall, Juan I Moliva, Ruth Hunegnaw, Guha Asthagiri Arunkumar, Clinton Ogega, Arshan Nasir, Hamilton Bennett, Joshua Johnson, Michael A. Durney, Guillaume Stewart-Jones, Jay W Hooper, Tonya Colpitts, Galit Alter, Nancy J. Sullivan, Andrea Carfi, Bernard Moss |
| Rok vydání: |
2022 |
| DOI: |
10.1101/2022.12.17.520886 |
| Popis: |
Monkeypox virus (MPXV) caused a global outbreak in 2022, fueled by behaviorally-altered and enhanced human-to-human transmission. While smallpox vaccines were rapidly deployed to curb spread and disease among those at highest risk, breakthrough disease was noted after complete immunization. Given the imminent threat of additional zoonotic events as well as the virus’ evolving ability to drive human-to-human transmission, there is an urgent need for the development of a MPXV-specific vaccine that is able to also confer broad protection against evolving strains and related orthopoxviruses. Here, we demonstrate that an mRNA-lipid nanoparticle vaccine encoding a set of four highly conserved MPXV surface proteins involved in virus attachment, entry and transmission can induce MPXV-specific immunity and heterologous protection against a lethal vaccinia virus (VACV) challenge. Compared to Modified Vaccinia Virus Ankara (MVA), which forms the basis for the current MPXV vaccine, mRNA-vaccination generated superior neutralizing and cellular spread-inhibitory activities against MPXV and VACV as well as greater Fc-effector Th1-biased humoral immunity to the four MPXV antigens and the four VACV homologs. Single MPXV antigen mRNA vaccines provided partial protection against VACV challenge, while combinations of two, three or four MPXV antigen expressing mRNAs protected against disease-related weight loss and death. Remarkably, the cross-protection by multivalent MPXV mRNAs was superior to the homologous protection by MVA, associated with a combination of neutralizing and non-neutralizing antibody functions. These data reveal robust protection against VACV using an mRNA-based vaccine targeting four highly conserved viral surface antigens, linked to the induction of highly functional antibodies able to rapidly control viral infection. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
